JP2017536414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536414A5 JP2017536414A5 JP2017545861A JP2017545861A JP2017536414A5 JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5 JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- acid sequence
- amino acid
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084003P | 2014-11-25 | 2014-11-25 | |
| US62/084,003 | 2014-11-25 | ||
| US201562147232P | 2015-04-14 | 2015-04-14 | |
| US62/147,232 | 2015-04-14 | ||
| US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
| US14/943,490 | 2015-11-17 | ||
| PCT/US2015/061543 WO2016085750A1 (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Division JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536414A JP2017536414A (ja) | 2017-12-07 |
| JP2017536414A5 true JP2017536414A5 (enExample) | 2018-12-27 |
Family
ID=56009149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545861A Pending JP2017536414A (ja) | 2014-11-25 | 2015-11-19 | 血管性眼疾患を処置するための方法および製剤 |
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160144025A1 (enExample) |
| EP (1) | EP3224278A4 (enExample) |
| JP (2) | JP2017536414A (enExample) |
| KR (1) | KR20170087950A (enExample) |
| CN (1) | CN107001457A (enExample) |
| AU (1) | AU2015353838A1 (enExample) |
| BR (1) | BR112017009807A2 (enExample) |
| CA (1) | CA2968522A1 (enExample) |
| CL (1) | CL2017001188A1 (enExample) |
| CO (1) | CO2017004715A2 (enExample) |
| EA (1) | EA201791168A1 (enExample) |
| IL (1) | IL252159B (enExample) |
| MA (2) | MA41028A (enExample) |
| MX (1) | MX2017006129A (enExample) |
| PE (1) | PE20170900A1 (enExample) |
| PH (1) | PH12017500834A1 (enExample) |
| SG (1) | SG11201703609UA (enExample) |
| WO (1) | WO2016085750A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2586459B1 (en) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| EP3753548A1 (en) | 2006-06-16 | 2020-12-23 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| SG10201505672TA (en) | 2009-07-06 | 2015-09-29 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| HK1218071A1 (zh) | 2013-02-21 | 2017-02-03 | Rsem, Limited Partnership | Sema3a在预防和治疗眼渗透性过高症中的抑制 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI761959B (zh) | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| CA2981021C (en) * | 2015-03-26 | 2020-11-17 | Eyekor, Llc | Image analysis |
| EP3352856B1 (en) | 2015-09-23 | 2021-08-18 | Aerpio Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc. | antibodies and conjugates thereof |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| US20200056186A1 (en) | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
| JPWO2018070390A1 (ja) * | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | 抗ｒｏｂｏ４抗体と他剤を含む組成物 |
| WO2018208625A1 (en) * | 2017-05-06 | 2018-11-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with aplnr antagonists and vegf inhibitors |
| US20190056350A1 (en) * | 2017-08-18 | 2019-02-21 | Regeneron Pharmaceuticals, Inc. | Image capillary isoelectric focusing to analyze protein variants in a sample matrix |
| IL274711B2 (en) * | 2017-11-30 | 2024-10-01 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| JP7692699B2 (ja) * | 2017-12-22 | 2025-06-16 | サムスン バイオエピス カンパニー リミテッド | Ｖｅｇｆアンタゴニストを含む液体組成物 |
| EP4495136A3 (en) | 2018-01-26 | 2025-04-23 | The Regents of the University of California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| CN119770646A (zh) * | 2018-02-06 | 2025-04-08 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| EP3761953A1 (en) * | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| CN112912104A (zh) * | 2018-08-17 | 2021-06-04 | 三钰生物科技股份有限公司 | 抗血管新生融合蛋白及其用途 |
| KR102467349B1 (ko) | 2018-10-29 | 2022-11-16 | 에프. 호프만-라 로슈 아게 | 항체 제형 |
| CN109598628B (zh) * | 2018-11-30 | 2022-09-20 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
| MX2021007393A (es) | 2018-12-18 | 2021-09-23 | Novartis Ag | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| US11253502B2 (en) | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
| KR20250051157A (ko) | 2019-06-05 | 2025-04-16 | 리제너론 파아마슈티컬스, 인크. | 정밀 투여량 전달을 위한 디바이스 및 방법 |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| CN115398559A (zh) * | 2020-04-29 | 2022-11-25 | 诺华股份有限公司 | 用于评估患者眼睛中疾病或病症的活动水平的计算机实施的系统和方法 |
| WO2021226444A2 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| JP2023530187A (ja) * | 2020-06-22 | 2023-07-13 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ａｎｇ－２抗体とその用途 |
| CN116056688A (zh) * | 2020-07-24 | 2023-05-02 | 盼展生物技术有限公司 | 眼用液体组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| EP3753548A1 (en) * | 2006-06-16 | 2020-12-23 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| US20120076787A1 (en) * | 2009-05-28 | 2012-03-29 | Peter Adamson | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| KR20200077622A (ko) | 2011-01-13 | 2020-06-30 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| AU2013212587B2 (en) | 2012-01-23 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| EP2872534B1 (en) * | 2012-07-13 | 2018-08-08 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| HUE053669T2 (hu) * | 2012-12-05 | 2021-07-28 | Novartis Ag | Készítmények és eljárások EPO-t célzó antitestekre |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| RU2676303C2 (ru) * | 2013-07-11 | 2018-12-27 | Новартис Аг | Использование антагониста vegf для лечения ретролентальной фиброплазии |
| US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| DE112014005747T5 (de) * | 2013-12-17 | 2016-10-06 | Kymab Limited | Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko not_active Withdrawn
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en not_active Ceased
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536414A5 (enExample) | ||
| JP2021046431A (ja) | 血管性眼疾患を処置するための方法および製剤 | |
| JP6367233B2 (ja) | 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用 | |
| US9926369B2 (en) | Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody | |
| CN102549015B (zh) | 针对人血管生成素-2的高亲和力人抗体 | |
| CA2870338C (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
| JP2020114218A5 (enExample) | ||
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2016504416A5 (enExample) | ||
| US9932397B2 (en) | VEGFA/Ang2 Compounds | |
| CN102027015A (zh) | 抗cxcr4抗体 | |
| JP2014532072A5 (enExample) | ||
| US20160152717A1 (en) | Methods for treating dry eye disease by administering an il-6r antagonist | |
| JP2020520912A (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| JP2021507677A5 (enExample) | ||
| JP2024528724A (ja) | 抗ｐｄ－１抗体医薬組成物及びその使用 | |
| JP6002354B1 (ja) | Ａｎｇ２抗体 | |
| US20240425574A1 (en) | Anti-pdgf-b antibodies and pharmaceutical composition thereof | |
| KR20130133274A (ko) | Tgf-알파 및 에피레굴린에 결합하는 항체 | |
| TWI859339B (zh) | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 | |
| JP2020518641A5 (enExample) | ||
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| EP4519317A1 (en) | Multispecific binding molecules and methods of use thereof | |
| RU2021125763A (ru) | Биспецифическое антитело, специфически связывающееся с vegf и ang2 |